TickerFacts.

Anavex Life Sciences Corp. (AVXL): Net Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2014-09-30, 2018-09-30 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$46.38M
Year ended 2025-09-30
-$13.02M
Trailing 12 months to 2026-06-30
2005-09-30: -$91.6K2006-09-30: -$25.5K2007-09-30: -$1.58M2008-09-30: -$5.35M2009-09-30: -$5.50M2010-09-30: -$8.78M2011-09-30: -$7.31M2012-09-30: -$8.30M2013-09-30: -$3.70M2014-09-30: -$9.97M2015-09-30: -$12.11M2016-09-30: -$14.74M2017-09-30: -$13.46M2018-09-30: -$17.25M2019-09-30: -$26.29M2020-09-30: -$26.28M2021-09-30: -$37.91M2022-09-30: -$47.98M2023-09-30: -$47.51M2024-09-30: -$43.00M2025-09-30: -$46.38M-$46.38M
2005-09-30 Net Income (USD) 2025-09-30
Period endedNet IncomeChange YoYSource filing
2025-09-30-$46.38Mn/m2026-08-28, From 2024-10-01
2024-09-30-$43.00Mn/m2026-08-28, From 2023-10-01
2023-09-30-$47.51Mn/m2026-08-28, From 2022-10-01
2022-09-30-$47.98Mn/m2023-11-27, From 2021-10-01
2021-09-30-$37.91Mn/m2023-11-27, From 2020-10-01
2020-09-30-$26.28Mn/m2022-11-28, From 2019-10-01
2019-09-30-$26.29Mn/m2020-12-28, From 2018-10-01
2018-09-30-$17.25Mn/c2019-12-16, From 2017-10-01
2017-09-30-$13.46Mn/m2019-01-25, From 2016-10-01
2016-09-30-$14.74Mn/m2019-01-25, From 2015-10-01
2015-09-30-$12.11Mn/m2017-12-11, From 2014-10-01
2014-09-30-$9.97Mn/c2016-12-14, From 2013-10-01
2013-09-30-$3.70Mn/m2014-12-29, From 2012-10-01
2012-09-30-$8.30Mn/m2013-12-30, From 2011-10-01
2011-09-30-$7.31Mn/m2013-12-30, From 2010-10-01
2010-09-30-$8.78Mn/m2013-12-30, From 2009-10-01
2009-09-30-$5.50Mn/m2013-12-30, From 2008-10-01
2008-09-30-$5.35Mn/m2013-12-30, From 2007-10-01
2007-09-30-$1.58Mn/m2013-12-30, From 2006-10-01
2006-09-30-$25.5Kn/m2013-12-30, From 2005-10-01
2005-09-30-$91.6Kn/a2013-12-30, From 2004-10-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
Anavex Life Sciences Corp. (AVXL)2025-09-30-$46.38Mn/m
Surrozen, Inc. (SRZN)2025-12-31-$242.03Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$63.53Mn/m
Zura Bio Ltd (ZURA)2025-12-31-$68.65Mn/m
Quince Therapeutics, Inc. (QNCX)2025-12-31-$83.98Mn/m
aTYR PHARMA INC (ATYR)2025-12-31-$74.12Mn/m
Humacyte, Inc. (HUMA)2025-12-31-$40.83Mn/m
LeonaBio, Inc. (LONA)2025-12-31-$105.61Mn/m
Aligos Therapeutics, Inc. (ALGS)2025-12-31-$24.19Mn/m

Compare AVXL, SRZN, LCTX, ZURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗